OBJECTIVES: This study hypothesized that there is an association between chronic stress (as indexed by resting amygdalar activity [AmygA]), hematopoietic system activity (HMPA), and subclinical cardiovascular indexes (aortic vascular inflammation [VI] and noncalcified coronary plaque burden [NCB]) in psoriasis (PSO). The study also hypothesized that treatment of PSO would improve these parameters. BACKGROUND: PSO is a stress-related chronic inflammatory condition that is associated with increased prevalence of subclinical cardiovascular disease (CVD). In individuals without PSO, stress has been linked to CVD through a serial biological pathway that involves the amygdala, hematopoietic tissues, and atherosclerotic plaques. METHODS: A total of 164 consecutive patients with PSO and 47 healthy volunteers underwent 18-fluorodeoxyglucose positron emission tomography/computed tomography scans for assessment of AmygA, HMPA, and VI, as well as coronary computed tomography angiography scans for quantifying NCB. Furthermore, a consecutive subset of 30 patients with severe PSO (Psoriasis Area Severity Index Score >10) were followed at 1 year to assess the relationship between skin disease improvement and AmygA, HMPA, VI, and NCB. RESULTS: The PSO cohort was middle-aged (mean age: 50 years), had low cardiovascular risk (Framingham risk score: median: 3) and had mild to moderate PSO activity (median Psoriasis Area Severity Index Score: 5.6). AmygA was higher in patients with PSO compared to volunteer participants. AmygA was associated with HMPA (bone marrow activity: β = 0.20, p = 0.01) and subclinical CVD (VI: β = 0.31, p < 0.001; NCB: β = 0.27, p < 0.001) The AmygA-CVD association was in part mediated by HMPA (VI: 20.9%, NCB: 36.7%). Following 1 year of PSO treatment in those with severe disease, improvement in skin disease was accompanied by a reduction in AmygA, bone marrow activity, and VI, with no progression of NCB. CONCLUSIONS: In PSO, a chronic inflammatory disease state, AmygA, which is a manifestation of chronic stress, substantially contributes to the risk of subclinical CVD. Additional studies that use psychometric measures of stress are required to explore therapeutic impact. Published by Elsevier Inc.
OBJECTIVES: This study hypothesized that there is an association between chronic stress (as indexed by resting amygdalar activity [AmygA]), hematopoietic system activity (HMPA), and subclinical cardiovascular indexes (aortic vascular inflammation [VI] and noncalcified coronary plaque burden [NCB]) in psoriasis (PSO). The study also hypothesized that treatment of PSO would improve these parameters. BACKGROUND: PSO is a stress-related chronic inflammatory condition that is associated with increased prevalence of subclinical cardiovascular disease (CVD). In individuals without PSO, stress has been linked to CVD through a serial biological pathway that involves the amygdala, hematopoietic tissues, and atherosclerotic plaques. METHODS: A total of 164 consecutive patients with PSO and 47 healthy volunteers underwent 18-fluorodeoxyglucose positron emission tomography/computed tomography scans for assessment of AmygA, HMPA, and VI, as well as coronary computed tomography angiography scans for quantifying NCB. Furthermore, a consecutive subset of 30 patients with severe PSO (Psoriasis Area Severity Index Score >10) were followed at 1 year to assess the relationship between skin disease improvement and AmygA, HMPA, VI, and NCB. RESULTS: The PSO cohort was middle-aged (mean age: 50 years), had low cardiovascular risk (Framingham risk score: median: 3) and had mild to moderate PSO activity (median Psoriasis Area Severity Index Score: 5.6). AmygA was higher in patients with PSO compared to volunteer participants. AmygA was associated with HMPA (bone marrow activity: β = 0.20, p = 0.01) and subclinical CVD (VI: β = 0.31, p < 0.001; NCB: β = 0.27, p < 0.001) The AmygA-CVD association was in part mediated by HMPA (VI: 20.9%, NCB: 36.7%). Following 1 year of PSO treatment in those with severe disease, improvement in skin disease was accompanied by a reduction in AmygA, bone marrow activity, and VI, with no progression of NCB. CONCLUSIONS: In PSO, a chronic inflammatory disease state, AmygA, which is a manifestation of chronic stress, substantially contributes to the risk of subclinical CVD. Additional studies that use psychometric measures of stress are required to explore therapeutic impact. Published by Elsevier Inc.
Authors: Michael T Osborne; Azar Radfar; Malek Z O Hassan; Shady Abohashem; Blake Oberfeld; Tomas Patrich; Brian Tung; Ying Wang; Amorina Ishai; James A Scott; Lisa M Shin; Zahi A Fayad; Karestan C Koenen; Sanjay Rajagopalan; Roger K Pitman; Ahmed Tawakol Journal: Eur Heart J Date: 2020-02-01 Impact factor: 29.983
Authors: Nidhi H Patel; Michael T Osborne; Heather Teague; Philip Parel; Mariya Svirydava; Alexander V Sorokin; Meron Teklu; Grigory Manyak; Wunan Zhou; Carla Pantoja; Colin Scott; Martin P Playford; Promita Kapoor; Justin A Rodante; Andrew Keel; Marcus Chen; Ahmed Tawakol; Nehal N Mehta Journal: Atherosclerosis Date: 2021-11-08 Impact factor: 5.162
Authors: Michael T Osborne; Lisa M Shin; Nehal N Mehta; Roger K Pitman; Zahi A Fayad; Ahmed Tawakol Journal: Circ Cardiovasc Imaging Date: 2020-08-14 Impact factor: 7.792
Authors: Tawseef Dar; Michael T Osborne; Shady Abohashem; Taimur Abbasi; Karmel W Choi; Ahmed Ghoneem; Nicki Naddaf; Jordan W Smoller; Roger K Pitman; John W Denninger; Lisa M Shin; Gregory Fricchione; Ahmed Tawakol Journal: Circ Cardiovasc Imaging Date: 2020-08-13 Impact factor: 7.792
Authors: Tawseef Dar; Azar Radfar; Shady Abohashem; Roger K Pitman; Ahmed Tawakol; Michael T Osborne Journal: Curr Treat Options Cardiovasc Med Date: 2019-04-26
Authors: Ahmed Tawakol; Michael T Osborne; Ying Wang; Basma Hammed; Brian Tung; Tomas Patrich; Blake Oberfeld; Amorina Ishai; Lisa M Shin; Matthias Nahrendorf; Erica T Warner; Jason Wasfy; Zahi A Fayad; Karestan Koenen; Paul M Ridker; Roger K Pitman; Katrina A Armstrong Journal: J Am Coll Cardiol Date: 2019-07-02 Impact factor: 24.094
Authors: Sundus S Lateef; Mina Al Najafi; Amit K Dey; Mariyam Batool; Khaled M Abdelrahman; Domingo E Uceda; Aarthi S Reddy; Maryia D Svirydava; Navya Nanda; Jenis E Ortiz; Nina Prakash; Justin A Rodante; Andrew Keel; Wunan Zhou; Marcus Y Chen; Martin P Playford; Heather L Teague; Ahmed A Tawakol; Joel M Gelfand; Tiffany M Powell-Wiley; Nehal N Mehta Journal: Atherosclerosis Date: 2020-07-29 Impact factor: 5.162
Authors: Peter J Gianaros; Thomas E Kraynak; Dora C-H Kuan; James J Gross; Kateri McRae; Ahmad R Hariri; Stephen B Manuck; Javier Rasero; Timothy D Verstynen Journal: Soc Cogn Affect Neurosci Date: 2020-11-10 Impact factor: 3.436
Authors: C Elise Kleyn; Peter S Talbot; Nehal N Mehta; Francesca Sampogna; Chris Bundy; Darren M Ashcroft; Alexa B Kimball; Peter C M van de Kerkhof; Christopher E M Griffiths; Fernando Valenzuela; Joelle M van der Walt; Tsion Aberra; Lluís Puig Journal: Acta Derm Venereol Date: 2020-01-07 Impact factor: 3.875